Clinical Trials
22 trialsNCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
NCT01661335 2021-03-23
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Phase 3 Completed
NCT00553059 2020-10-09
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00016380 2020-04-03
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Canadian Cancer Trials Group
Phase 3 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00601172 2018-01-17
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
GlaxoSmithKline
Phase 3 Completed
NCT00431236 2017-08-22
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Completed
NCT00343863 2017-07-11
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
University of Washington
Phase NA Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00687011 2017-05-15
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT00880191 2016-07-06
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01490060 2016-04-11
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
M.D. Anderson Cancer Center
Phase NA Completed
NCT00293384 2016-03-15
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT01074697 2015-04-24
GAND-emesis
Odense University Hospital
Phase 3 Completed
NCT00314743 2013-05-24
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
Washington University School of Medicine
Phase EARLY_PHASE1 Completed
NCT00410488 2013-03-22
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
M.D. Anderson Cancer Center
Phase NA Completed
NCT00003213 2012-07-11
Drugs to Reduce the Side Effects of Chemotherapy
Swiss Cancer Institute
Phase 3 Completed
NCT00152867 2012-06-28
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
University Health Network, Toronto
Phase 3 Completed
NCT00169572 2010-05-10
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline
Phase 2 Completed